Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Free Cash Flow (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Free Cash Flow for 10 consecutive years, with -$25.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 34.73% to -$25.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$115.7 million, a 1.58% decrease, with the full-year FY2025 number at -$116.6 million, down 2.41% from a year prior.
  • Free Cash Flow was -$25.4 million for Q4 2025 at Rhythm Pharmaceuticals, up from -$26.6 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$18.8 million in Q4 2024 to a low of -$53.8 million in Q1 2022.
  • A 5-year average of -$34.3 million and a median of -$33.8 million in 2021 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: crashed 60.27% in 2022, then soared 37.87% in 2023.
  • Rhythm Pharmaceuticals' Free Cash Flow stood at -$40.5 million in 2021, then increased by 16.13% to -$34.0 million in 2022, then grew by 13.58% to -$29.4 million in 2023, then soared by 35.86% to -$18.8 million in 2024, then crashed by 34.73% to -$25.4 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Free Cash Flow are -$25.4 million (Q4 2025), -$26.6 million (Q3 2025), and -$23.3 million (Q2 2025).